Metrochem API Private Limited Metrochem API Private Limited

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ImmunoBiochem","sponsor":"Immunogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by ImmunoBiochem

    Menu

    ImmunoBiochem

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ImmunoBiochem

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates

              Details:

              The collaboration will combine ImmunoGen's proprietary linker-payload technology with ImmunoBiochem's antibodies directed against specific targets to develop next-generation antibody-drug conjugates.

              Lead Product(s): Antibody-drug Conjugate

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Immunogen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Veranova: A CDMO that manages complexity with confidence.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY